This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Cooley anaemia쿠울리빈혈

ICD-10: D56.1 | Synonyms: Cooley anemia, Cooley's anemia, Thalassemia major, Beta-thalassemia major, severe thalassemia

Contents
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

Life of Thomas Cooley and the first clinical description

Thomas Benton Cooley (1871–1945) was a pediatrician from Michigan, USA, who studied medicine at the University of Michigan, trained in Germany, and then worked for about 30 years at the Children's Hospital of Michigan in Detroit. As a meticulous clinical observer, he carefully noted the pattern of severe anemia, jaundice, splenomegaly, and distinctive deformities of the skull and facial skeleton that recurred in children of the Italian immigrant families he treated. Cooley was also devoted to child welfare and was a distinguished scholar who served as president of the American Pediatric Society.

The landmark 1925 paper

In 1925, Cooley and his colleague P. Lee published A series of cases of splenomegaly in children with anemia and peculiar bone changes in the Transactions of the American Pediatric Society. In this paper, they described a new syndrome in 5 children of Italian immigrants who commonly showed ① severe anemia, ② marked splenomegaly, and ③ peculiar radiographic findings of the skeleton (thinning of the bone cortex, widening of the marrow cavity). This clinical description corresponds to what is now beta-thalassemia major (thalassemia major), and the name 'Cooley's anemia' originated here.

Transition to the name thalassemia

In the 1930s, hematologists in Italy and Greece began to report that the same disease occurred at very high frequency in Mediterranean countries. In 1936, Whipple and Bradford identified bone marrow hyperplasia (erythroblastic hyperplasia) as the pathological mechanism of this disease. Reflecting the contributions of Italian hematologists, the name thalassemia, derived from the Greek 'sea (thalassa)' and 'blood (haima)', gradually came into use as the international standard term. Later, as advances in molecular biology in the 1950s–1970s distinguished alpha-thalassemia from beta-thalassemia, Cooley's anemia became established as a historical synonym for beta-thalassemia major.

Cooley's legacy and the name today

Cooley died in 1945, but his name continues to be remembered in the field of thalassemia. The Cooley's Anemia Foundation (now Thalassemia International Federation USA), a major thalassemia patient support organization in the United States, is named after him. In current medical literature, the names 'Cooley anaemia' or 'Cooley's anemia' are used as historical synonyms for thalassemia major, and they are also listed as inclusion terms under code D56.1 in ICD-10. In modern clinical practice, 'beta-thalassemia major' is the standard term, but 'Cooley anaemia' remains a valuable name in historical and educational contexts.

2. Causes

HBB gene mutations and loss of the beta-globin chain

The cause of Cooley anemia, that is, beta-thalassemia major, is the presence of pathogenic variants in both alleles of the HBB gene (11p15.4), which markedly reduces or completely abolishes beta-globin chain synthesis. Expression of the major form generally requires β0/β0 (homozygote) or β0/β+ (compound heterozygote, when the β+ allele causes a severe reduction in synthesis). The patients Cooley first described were of Italian descent and are presumed to have carried β0 variants common in Italy (codon 39 nonsense variant, IVS-I-110 splicing variant, etc.).

Cascade of pathology caused by loss of beta-globin synthesis

As HbA (α2β2) synthesis becomes virtually impossible, excess alpha chains form insoluble aggregates that destroy erythroid precursors. This ineffective erythropoiesis causes bone marrow hyperplasia, eventually leading to skeletal deformities and extramedullary hematopoiesis. The 'hair-on-end' radiographic finding of the skull and splenomegaly already observed in the patients Cooley described in 1925 are precisely the clinical manifestations of this pathological mechanism.

3. Genetics

The HBB gene and autosomal recessive inheritance

The genetic basis of Cooley anemia (beta-thalassemia major) is autosomal recessive variants of the HBB gene (11p15.4). Expression of the major form requires both parents to be heterozygous carriers (β-thal trait, thalassemia minor). The Italian children Cooley described in 1925 are understood to have been born in a homozygous or compound heterozygous state to two Italian heterozygous carrier parents. This is consistent with the epidemiological fact that the frequency of β-thal trait carriers is high in Mediterranean populations (12% in some regions of Italy, 8–10% in Sardinia, 7% in Greece), so the risk of having a child with the major form is relatively high.

HBB variants common in Italy

The HBB variants most commonly observed in Italy are as follows: ① codon 39 (CAG→TAG) nonsense variant, ② IVS-I-110 (G→A) splicing variant, ③ IVS-I-6 (T→C) splicing variant. Of these, codon 39 and IVS-I-110 in particular are commonly found in Italy, Sardinia, and Sicily, and are presumed to have predominated in the Italian immigrant patients Cooley first observed.

Modifier genes and the HbF effect

Even among patients with the same β0/β0 genotype, clinical severity differs. This is due to the influence of modifier genes that regulate the capacity for persistent fetal hemoglobin (HbF) production (BCL11A regulatory variants, XmnI polymorphism, KLF1 variants, etc.). HbF binds alpha chains and buffers the excess alpha chains, partially alleviating ineffective erythropoiesis. This fact is the basis for the attention given to HbF reactivation as a therapeutic strategy.

4. General epidemiology

Worldwide distribution

It is estimated that about 60,000–70,000 infants with Cooley anemia (beta-thalassemia major) are born worldwide each year. The number of heterozygous carriers (thalassemia minor) reaches about 288 million. It is particularly common in the Mediterranean region (Italy, Greece, Cyprus, Sardinia), the Middle East (Iran, Turkey, Iraq), South Asia (India, Pakistan), and Southeast Asia (Thailand, Malaysia, Indonesia), which is directly linked to the geographic background of the Italian immigrant patients Cooley first described.

Cyprus and high-prevalence Mediterranean regions

Cyprus is one of the countries with the highest frequency of beta-thalassemia carriers in the world, with about 14% of the population being heterozygous carriers. Until the 1970s, 50–70 newborns with thalassemia major were born each year in Cyprus. This dramatic figure decreased by more than 90% after national carrier screening and prenatal diagnosis programs were introduced in the 1970s. In Italy as well, births of infants with thalassemia major have decreased markedly through prevention programs since the 1990s.

Status in Korea and Asia

In East Asia, including Korea, Cooley anemia is very rare. However, with the increase in multicultural families and immigrants of Southeast and South Asian background, diagnosed cases are gradually increasing in Korea as well. Prenatal screening of pregnant women of high-risk ethnic backgrounds and improved access to precise genetic testing are emerging as major tasks for the management system in Korea.

5. Pathophysiology

Alpha-chain excess and intracellular toxicity

When little or no beta-globin is synthesized, the alpha chains produced cannot pair with beta chains and accumulate in the cytoplasm. These excess alpha chains form insoluble precipitates that bind to the red cell membrane and cross-link abnormally with membrane proteins (spectrin, band 3, etc.), damaging the structural integrity of the membrane. As a result, erythroid precursors (erythroblasts) are destroyed in the bone marrow before completing maturation, and this process is the core of ineffective erythropoiesis.

Systemic consequences of ineffective erythropoiesis

When the number of circulating red blood cells decreases markedly due to ineffective erythropoiesis, the body greatly increases erythropoietin (EPO) secretion, overstimulating the bone marrow. This causes skeletal deformities in which the marrow cavities of the skull, spine, ribs, and limb bones expand and the cortex thins. In particular, expansion of the facial bones (maxilla, zygoma, frontal bone) is the basis of the 'peculiar skeletal deformities' Cooley described in 1925 and appears as the characteristic facial deformity now known as 'chipmunk face'. Extramedullary hematopoiesis is also activated in the spleen and liver, causing massive organomegaly.

Development of iron overload

Ineffective erythropoiesis suppresses the synthesis of hepcidin, which inhibits iron absorption, so intestinal iron absorption increases pathologically. Regular transfusion also directly supplies iron in the form of heme iron, worsening iron overload. Excess iron generates free radicals that cause oxidative damage to cardiomyocytes, hepatocytes, pancreatic β cells, the pituitary gland, thyroid, gonads, and others, and this was the main cause of death of patients with Cooley anemia before iron chelation therapy was developed.

6. Symptoms

Onset after 6 months to 1 year of age

The main symptoms of Cooley anemia appear when maternally derived fetal hemoglobin (HbF: α2γ2) switches to adult-type HbA, that is, after 6 months to 1 year of age. From this time, beta-chain deficiency begins to manifest clinically, and progressively worsening anemia appears. Pallor, jaundice, decreased appetite, poor growth, and frequent infections are early symptoms. Abdominal distension (due to splenomegaly and hepatomegaly) is prominent, and if left untreated, transfusion dependence develops within weeks to months.

Skeletal and facial deformities

When transfusion therapy is not given or is insufficient, characteristic skeletal deformities develop due to bone marrow hyperplasia from ineffective erythropoiesis. In the skull, thinning of the frontal, parietal, and temporal cortices and a radiographic brush-like pattern ('hair-on-end or crew-cut appearance') appear. In the face, protrusion due to expansion of the maxilla, enlargement of the zygomatic bones, flattening of the nasal bridge, and protrusion of the anterior teeth produce a distinctive facial appearance ('chipmunk face'). These are exactly the 'peculiar skeletal deformities' Cooley described in 1925. Radiographic cortical thinning and hyperplastic marrow findings are also observed in the spine, ribs, and long bones.

Symptoms of complications due to iron overload

Even in treated patients, as iron overload from transfusion and ineffective erythropoiesis progresses over a long period, endocrine disorders (growth hormone deficiency, hypothyroidism, diabetes, hypoparathyroidism), arrhythmia and heart failure due to cardiac iron overload, and liver fibrosis and cirrhosis develop. Skin pigmentation (bronze skin) is the clinical expression of iron deposition in the skin.

7. Signs

Characteristic physical examination findings

The typical physical examination findings of Cooley anemia are pallor, jaundice, splenomegaly, and chipmunk face. Pallor and jaundice are expressions of chronic hemolytic anemia, and splenomegaly may progress to massive splenomegaly due to extramedullary hematopoiesis and hemophagocytosis. Depending on the treatment course, growth retardation and delayed sexual development (hypogonadism due to iron overload) are observed.

Hematologic test findings

The complete blood count shows severe anemia with Hb 2–7 g/dL and markedly decreased MCV and MCH (microcytosis, hypochromia). The peripheral blood smear characteristically shows target cells, nucleated red blood cells (nucleated RBC), polychromatic red cells, anisocytosis, and poikilocytosis. Reticulocytes are increased but may be lower than expected for the degree of anemia due to ineffective erythropoiesis. HPLC shows markedly elevated HbF (10–90%), absent or extremely reduced HbA, and normal to slightly increased HbA2.

Radiographic and imaging findings

Skull X-rays show a 'hair-on-end' or 'crew-cut' appearance. Spine X-rays show fish-mouth vertebrae, and cortical thinning is seen in the long bones. Abdominal ultrasound reveals massive splenomegaly and hepatomegaly. In chronically transfused patients, cardiac MRI T2* is the key imaging method for assessing cardiac iron overload.

8. Screening

Historical development of screening of pregnant women and prenatal screening

Screening systems for the prevention of Cooley anemia were first systematized in high-prevalence Mediterranean countries. In the 1970s, a national screening program for pregnant women was first introduced in Cyprus, and it subsequently spread to Sardinia (Italy), Greece, Iran, and mainland Italy. These screening programs operate as a system in which heterozygous carriers are identified by blood tests (CBC and hemoglobin electrophoresis) before or in early pregnancy, and prenatal genetic testing is performed in carrier couples.

Screening tests for carrier identification

The first-line screening test for identifying heterozygous carriers (thalassemia minor) is confirming decreased MCV (<80 fL) and MCH (<27 pg) on a CBC. When microcytosis and hypochromia are confirmed, β-thal trait is diagnosed by confirming HbA2 ≥3.5% on hemoglobin HPLC. Iron deficiency anemia (another cause of microcytosis and hypochromia) is differentiated by serum ferritin. When both partners have β-thal trait, prenatal genetic testing is strongly recommended.

Screening of high-risk populations

In pregnant women and their partners of Mediterranean, Middle Eastern, South Asian, or Southeast Asian background, β-thal trait screening is recommended from the pregnancy planning stage. In Korea as well, prenatal screening guidelines for pregnant women of high-risk ethnic backgrounds should be supplemented, and strengthening of the diagnostic system is required in line with the increase in multicultural families.

9. Diagnosis

Hematologic diagnosis

The clinical diagnosis of Cooley anemia (thalassemia major) is made by the combination of severe microcytic anemia (Hb 2–7 g/dL) + markedly elevated HbF on HPLC + absent/reduced HbA + onset at 6–12 months of age. The peripheral blood smear shows target cells, nucleated red blood cells, and a low reticulocyte percentage (reflecting ineffective erythropoiesis). HPLC is the standard method for quantifying the HbA, HbA2, and HbF fractions.

Molecular genetic confirmation

Molecular analysis of the HBB gene is essential for confirming Cooley anemia and determining the exact genotype. Ethnicity-specific variant panel testing (ARMS-PCR, reverse dot-blot hybridization) or Sanger sequencing of the entire coding region of the HBB gene is performed. Prenatal diagnosis confirms HBB gene variants in fetal DNA by CVS (10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation). Preimplantation genetic testing (PGT-M) is also possible with in vitro fertilization.

Differential diagnosis

In the differential diagnosis of severe anemia in infancy, other congenital hemolytic anemias (spherocytosis, G6PD deficiency, PK deficiency), iron deficiency anemia (severe), and other hemoglobin disorders (HbE/β-thal, sickle-β-thalassemia) should be considered. Most can be differentiated by HPLC and molecular genetic testing.

10. Treatment

Regular transfusion therapy

The core treatment of Cooley anemia is regular transfusion. The goal of transfusion is to maintain a pretransfusion Hb ≥9–10 g/dL to suppress ineffective erythropoiesis and prevent progression of skeletal deformities and hepatosplenomegaly. The transfusion interval is usually 2–4 weeks, and the cumulative transfusion volume reaches about 150–200 mL/kg of body weight per year. To prevent alloimmunization, use of packed red blood cells matched for ABO, Rh (CcEe), and Kell antigens is recommended.

Iron chelation therapy

Iron chelation therapy is essential to prevent and treat iron overload due to regular transfusion. Currently available iron chelators are deferoxamine (subcutaneous or intravenous injection, infused 8–12 hours daily), deferasirox (Exjade/Jadenu, orally once daily), and deferiprone (orally three times daily), which are selected or combined according to the individual patient's degree of iron overload, adherence, and adverse effect profile. The criterion for starting iron chelation is usually a serum ferritin >1,000 ng/mL or after 2 years of regular transfusion.

Hematopoietic stem cell transplantation

The curative treatment, allogeneic hematopoietic stem cell transplantation (allogeneic HSCT), yields long-term survival of 80–90% with an HLA-matched sibling donor transplant and a cure rate of over 80% after graft rejection and graft-versus-host disease (GVHD). Transplant risk and prognosis are predicted using the Pesaro classification (classes I–III: presence of hepatomegaly, portal fibrosis, chelation compliance). Transplant success rates are highest in class I (lowest-risk) patients. Outcomes of unrelated-donor and haploidentical transplants are also gradually improving.

Splenectomy and supportive care

Splenectomy is considered when transfusion requirements increase sharply due to hypersplenism. After splenectomy, pneumococcal, meningococcal, and Hib vaccination and prophylactic penicillin are needed to prevent infection with encapsulated bacteria. Vitamin D and calcium supplementation to prevent osteoporosis and monitoring of endocrine function (thyroid, parathyroid, gonads, pancreas) are also important supportive measures.

11. Prognosis

Historical prognosis and modern improvement

Most of the patients Cooley first described in 1925 died in childhood without modern treatments such as transfusion or iron chelation. Heart failure due to severe anemia, infection, and liver failure were the main causes of death. With the introduction of transfusion therapy in the 1950s–1960s, patient survival was prolonged, but transfusion-related iron overload emerged as a new major cause of death. Since the introduction of deferoxamine chelation in the 1970s, life expectancy has improved greatly, and the life expectancy of patients receiving appropriate treatment has now been extended to their 40s–50s.

Changes in prognosis with advances in treatment

Patients who undergo successful hematopoietic stem cell transplantation (HSCT) achieve transfusion independence, and long-term cure is possible. As clinical use expands of the gene therapy betibeglogene autotemcel (Zynteglo), approved in 2022, and Casgevy, approved in 2023, the quality of life and prognosis of patients maintaining long-term transfusion independence are expected to improve greatly.

Complication-related prognosis

Currently, the main cause of death in patients with Cooley anemia is heart failure due to cardiac siderosis (iron-induced cardiomyopathy). With cardiac MRI T2* monitoring and aggressive iron chelation, the incidence of cardiac complications has decreased greatly. Endocrine complications such as liver cirrhosis and diabetes are also major complications that require management in long-term survivors.

12. Prevention

History and success stories of Cooley anemia prevention

The history of Cooley anemia prevention goes hand in hand with national efforts in high-prevalence Mediterranean countries. Cyprus was the first to introduce a nationwide carrier screening program in 1973, reducing the birth rate of thalassemia major to virtually zero by 1985. This success spread to Italy (Sardinia), Greece, Iran, Turkey, and elsewhere, and in countries where active prevention policies were introduced early, new births of thalassemia major decreased by 90–97%.

Genetic counseling and prenatal diagnosis

In heterozygous carrier couples, each pregnancy has a 25% probability of a child with thalassemia major. Prenatal genetic testing by CVS (10–13 weeks of pregnancy) or amniocentesis (15–20 weeks of pregnancy) is standard. With in vitro fertilization, PGT-M (preimplantation genetic testing) can prevent implantation of affected embryos. Sufficient medical and ethical counseling must precede all of these choices.

Prevention of complications in affected patients

In patients already diagnosed, the following are recommended to prevent complications: ① adherence to transfusion protocols, ② maintaining compliance with iron chelation therapy, ③ vaccination and prophylactic antibiotics with splenectomy, ④ regular monitoring of the heart, liver, and endocrine organs (serum ferritin, cardiac MRI T2*, liver MRI T2*, endocrine function tests), ⑤ osteoporosis prevention (vitamin D and calcium supplementation, regular dual-energy X-ray absorptiometry), and ⑥ thrombosis prevention (aspirin, etc. after splenectomy).

13. References

  1. Cooley TB, Lee P. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc. 1925;37:29-30.
  2. Whipple GH, Bradford WL. Mediterranean disease—thalassemia (erythroblastic anemia of Cooley): associated pigment abnormalities simulating hemochromatosis. J Pediatr. 1936;9(3):279-311.
  3. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes. 4th ed. Blackwell Science; 2001.
  4. Cappellini MD, Cohen A, Porter J, Taher A, Viprakasit V, eds. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 4th ed. Thalassaemia International Federation; 2021.
  5. Lucarelli G, Galimberti M, Polchi P, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med. 1990;322(7):417-421.
  6. Cao A, Galanello R. Beta-thalassemia. Genet Med. 2010;12(2):61-76.
  7. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155-167.
  8. Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet. 2012;379(9813):373-383.
  9. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
  10. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480-487.
  11. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med. 2005;353(11):1135-1146.
  12. Kattamis A, Forni GL, Aydinok Y, Viprakasit V. Changing patterns in the epidemiology of beta-thalassemia. Eur J Haematol. 2020;105(6):692-703.